CP 96021
Latest Information Update: 25 Jan 2007
Price :
$50 *
At a glance
- Originator Pfizer
- Class Antiasthmatics
- Mechanism of Action Leukotriene D4 receptor antagonists; Platelet activating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma